These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
135 related items for PubMed ID: 20039885
1. d3-GHR genotype does not explain heterogeneity in GH responsiveness in hypopituitary adults. Moyes VJ, Walker DM, Owusu-Antwi S, Maher KT, Metherell L, Akker SA, Monson JP, Clark AJ, Drake WM. Clin Endocrinol (Oxf); 2010 Jun; 72(6):807-13. PubMed ID: 20039885 [Abstract] [Full Text] [Related]
2. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children. Binder G, Baur F, Schweizer R, Ranke MB. J Clin Endocrinol Metab; 2006 Feb; 91(2):659-64. PubMed ID: 16291706 [Abstract] [Full Text] [Related]
3. The d3/fl-GH receptor gene polymorphism does not influence quality of life and body composition in GH-deficient adults receiving GH replacement therapy. Adetunji OR, MacFarlane IA, Javadpour M, Alfirevic A, Pirmohamed M, Blair JC. Eur J Endocrinol; 2009 Oct; 161(4):541-6. PubMed ID: 19605543 [Abstract] [Full Text] [Related]
4. Influence of the d3-growth hormone (GH) receptor isoform on short-term and long-term treatment response to GH replacement in GH-deficient adults. van der Klaauw AA, van der Straaten T, Baak-Pablo R, Biermasz NR, Guchelaar HJ, Pereira AM, Smit JW, Romijn JA. J Clin Endocrinol Metab; 2008 Jul; 93(7):2828-34. PubMed ID: 18397980 [Abstract] [Full Text] [Related]
5. Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency. Barbosa EJ, Palming J, Glad CA, Filipsson H, Koranyi J, Bengtsson BA, Carlsson LM, Boguszewski CL, Johannsson G. J Clin Endocrinol Metab; 2009 Feb; 94(2):639-44. PubMed ID: 19050057 [Abstract] [Full Text] [Related]
6. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study. Baş F, Darendeliler F, Aycan Z, Çetinkaya E, Berberoğlu M, Sıklar Z, Öcal G, Timirci Ö, Çetinkaya S, Darcan Ş, Gökşen Şimşek D, Bideci A, Cinaz P, Böber E, Demir K, Bereket A, Turan S, Atabek ME, Tütüncüler F, Isbir T, Bozkurt N, Kabataş Eryılmaz S, Uzunhan O, Küçükemre Aydın B, Bundak R. Horm Res Paediatr; 2012 Feb; 77(2):85-93. PubMed ID: 22456308 [Abstract] [Full Text] [Related]
7. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults. Meyer S, Schaefer S, Stolk L, Arp P, Uitterlinden AG, Plöckinger U, Stalla GK, Tuschy U, Weber MM, Weise A, Pfützner A, Kann PH. Pharmacogenomics; 2009 Oct; 10(10):1599-608. PubMed ID: 19842933 [Abstract] [Full Text] [Related]
8. Short- and long-term responsiveness to low dose growth hormone (GH) in adult GH deficiency: Role of GH receptor polymorphism. Bianchi A, Giampietro A, Tartaglione L, Chiloiro S, Gentilella R, Bima C, Anile C, Olivi A, Pontecorvi A, De Marinis L. J Neuroendocrinol; 2019 Apr; 31(4):e12692. PubMed ID: 30712287 [Abstract] [Full Text] [Related]
9. Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients. Mormando M, Chiloiro S, Bianchi A, Giampietro A, Angelini F, Tartaglione L, Nasto L, Milardi D, Formenti AM, Giustina A, De Marinis L. Clin Endocrinol (Oxf); 2016 Nov; 85(5):717-724. PubMed ID: 27437620 [Abstract] [Full Text] [Related]
10. The common exon 3 polymorphism of the growth hormone receptor gene and the effect of growth hormone therapy on growth in Korean patients with Turner syndrome. Ko JM, Kim JM, Cheon CK, Kim DH, Lee DY, Cheong WY, Kim EY, Park MJ, Yoo HW. Clin Endocrinol (Oxf); 2010 Feb; 72(2):196-202. PubMed ID: 19681916 [Abstract] [Full Text] [Related]
11. The interactive effect of GHR-exon 3 and -202 A/C IGFBP3 polymorphisms on rhGH responsiveness and treatment outcomes in patients with Turner syndrome. Braz AF, Costalonga EF, Montenegro LR, Trarbach EB, Antonini SR, Malaquias AC, Ramos ES, Mendonca BB, Arnhold IJ, Jorge AA. J Clin Endocrinol Metab; 2012 Apr; 97(4):E671-7. PubMed ID: 22278433 [Abstract] [Full Text] [Related]
12. Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis. Wassenaar MJ, Dekkers OM, Pereira AM, Wit JM, Smit JW, Biermasz NR, Romijn JA. J Clin Endocrinol Metab; 2009 Oct; 94(10):3721-30. PubMed ID: 19584188 [Abstract] [Full Text] [Related]
13. The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor. Blum WF, Machinis K, Shavrikova EP, Keller A, Stobbe H, Pfaeffle RW, Amselem S. J Clin Endocrinol Metab; 2006 Oct; 91(10):4171-4. PubMed ID: 16868057 [Abstract] [Full Text] [Related]
14. Influence of growth hormone (GH) receptor deletion of exon 3 and full-length isoforms on GH response and final height in patients with severe GH deficiency. Räz B, Janner M, Petkovic V, Lochmatter D, Eblé A, Dattani MT, Hindmarsh PC, Flück CE, Mullis PE. J Clin Endocrinol Metab; 2008 Mar; 93(3):974-80. PubMed ID: 18029459 [Abstract] [Full Text] [Related]
15. Influence of the exon 3 deletion of GH receptor and IGF-I level at diagnosis on the efficacy and safety of treatment with somatotropin in adults with GH deficiency. Andujar-Plata P, Fernandez-Rodriguez E, Quinteiro C, Casanueva FF, Bernabeu I. Pituitary; 2015 Feb; 18(1):101-7. PubMed ID: 24710993 [Abstract] [Full Text] [Related]
16. Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH Therapy in Short Small-for-Gestational-Age Children. Carrascosa A, Audí L, Esteban C, Fernández-Cancio M, Andaluz P, Gussinyé M, Clemente M, Yeste D, Albisu MA. J Clin Endocrinol Metab; 2008 Jan; 93(1):147-53. PubMed ID: 17925340 [Abstract] [Full Text] [Related]
17. The impact of the d3-growth hormone receptor (d3-GHR) polymorphism on the therapeutic effect of growth hormone replacement in children with idiopathic growth hormone deficiency in Poland. Szmit-Domagalska J, Petriczko E, Drozdzynska M, Adler G, Horodnicka-Jozwa A, Ciechanowicz A, Walczak M. Neuro Endocrinol Lett; 2016 Sep; 37(4):282-288. PubMed ID: 27857044 [Abstract] [Full Text] [Related]
18. The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study. Audí L, Carrascosa A, Esteban C, Fernández-Cancio M, Andaluz P, Yeste D, Espadero R, Granada ML, Wollmann H, Fryklund L, Spanish SGA Study Group. J Clin Endocrinol Metab; 2008 Jul; 93(7):2709-15. PubMed ID: 18445665 [Abstract] [Full Text] [Related]
19. Homozygosity of the d3-growth hormone receptor polymorphism is associated with a high total effect of GH on growth and a low BMI in girls with Turner syndrome. Binder G, Trebar B, Baur F, Schweizer R, Ranke MB. Clin Endocrinol (Oxf); 2008 Apr; 68(4):567-72. PubMed ID: 17973940 [Abstract] [Full Text] [Related]
20. GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism. Tauber M, Ester W, Auriol F, Molinas C, Fauvel J, Caliebe J, Nugent T, Fryklund L, Ranke MB, Savage MO, Clark AJ, Johnston LB, Hokken-Koelega AC, NESTEGG group. Clin Endocrinol (Oxf); 2007 Sep; 67(3):457-61. PubMed ID: 17555507 [Abstract] [Full Text] [Related] Page: [Next] [New Search]